Abdullah Dogan

Abdullah Dogan

Auto-generated profile, based on publicly available information

Abdullah Dogan

Department of Cardiovascular Surgery, Acibadem Bakirkoy Hospital, Istanbul, Turkey

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2008 in Coronary Artery Disease
Verified
Journal Article
Closed access
ADAbdullah Dogan
Abdullah Dogan
NTNurullah Tuzun
Nurullah Tuzun
YTYasin Turker
Yasin Turker
SASelahattin Akcay
Selahattin Akcay
SKSelcuk Kaya
Selcuk Kaya
MOMehmet Ozaydin
Mehmet Ozaydin
Although underlying mechanisms of coronary artery ectasia (CAE) are clearly unknown, destruction of extracellular matrix may be responsible for the ectasia formation. Thus, we investigated the role of matrix metalloproteinases (MMP), tissue inhibitor of matrix metalloproteinases (TIMP-1), and inflammatory markers [high-sensitive C-reactive protein, interleukins (ILs)] in CAE patients. This study consisted of 28 consecutive CAE patients, 27 obstructive coronary artery disease (CAD) patients, and 22 controls with normal coronary arteries undergoing cardiac catheterization. Plasma levels of MMP-3, MMP-9, TIMP-1, and inflammatory markers were measured. Plasma level of MMP-3 was significantly higher in CAE patients compared with both CAD patients and controls (17.2+/-6.1, 11.2+/-3.2, and 9.2+/-3.4 ng/ml, respectively, both P=0.001) and so did MMP-9 level (27.4+/-5.9, 24.8+/-4.4, and 20.6+/-4.6 ng/ml, respectively, both P<0.05). IL-6 level was also higher in CAE patients than in controls (60.9+/-22.1 vs. 36.1+/-21.5 pg/ml, P=0.001) but were comparable in CAE and CAD patients. Plasma high-sensitive C-reactive protein, IL-1, and TIMP-1 levels were similar in three groups. MMP-3 levels correlated with diffuse (r=0.46, P=0.01) and multivessel ectasia (r=0.45, P=0.02). Our results suggest that the increased level of MMP-3, MMP-9, and IL-6 may be responsible for ectasia formation in patients with CAE.

1 August 2005 in European Journal of Heart Failure
Verified
Journal Article
Closed access
EVErcan Varol
Ercan Varol
MOMehmet Ozaydin
Mehmet Ozaydin
ADAbdullah Dogan
Abdullah Dogan
FKFeridun Kosar
Feridun Kosar
Background: Carbohydrate Antigen 125 (CA 125), a marker for ovarian cancer has been reported to increase in relation to the severity of heart failure. Objective: To evaluate the serum levels of CA 125 and other tumour markers, in patients with chronic heart failure. Methods: Blood levels of CA 125 and other tumour markers were determined in 44 heart failure patients (16 males and 28 females; age 66.3±6.5 years) before and after optimal medical treatment. Levels were also evaluated in 30 healthy volunteers (11 males and 19 females; age 65.7±9.8 years). The results in the heart failure patients were grouped according to clinical status (New York Heart Association Class). The mean duration of follow-up was 3±1.5 months. Results: The mean serum level of CA 125 was 81.9±91 in the patient group and 7.5±4.8 in control group (p<0.001). The mean CA 19-9 level in the patient group (16.8±16.6) was significantly higher than in the control group (4.5±2.6) (p<0.001). CA 125 levels increased as the New York Heart Association (NYHA) functional class increased (Class I/II: 17.7±22.4 U/ml; Class III: 99.6±92.1 U/ml; Class IV 136.4±102.8 U/ml; p<0.05). There were no significant differences in serum CA 125 and other tumour marker levels before and after optimisation of treatment. Significantly higher serum CA 125 levels were found in patients with pericardial effusion (p=0.002) when compared to patients without pericardial effusion. Conclusion: Among the tumour markers evaluated, only CA 125 seems to be specifically related to the presence and severity of heart failure and also the presence of pericardial fluid. Therefore, measurements of CA 125 serum levels might be proposed for the serial assessment of heart failure. Whether CA 125 has a specific biological role in heart failure requires further investigation.

18 October 2004 in Echocardiography
Verified
Journal Article
Closed access
PDF file
AAAlaettin Avsar
Alaettin Avsar
ADAbdullah Dogan
Abdullah Dogan
TTTalat Tavli
Talat Tavli

5 August 2004 in Echocardiography
Verified
Journal Article
Closed access
PDF file
ADAbdullah Dogan
Abdullah Dogan
HKHalil Kahraman
Halil Kahraman
MOMustafa Ozturk
Mustafa Ozturk
AAAlaettin Avsar
Alaettin Avsar

1 February 2004 in The American Journal of Cardiology
Verified
Journal Article
Closed access
ADAbdullah Dogan
Abdullah Dogan
AAAlaettin Avsar
Alaettin Avsar
MOMustafa Ozturk
Mustafa Ozturk

1 June 2012 in Blood Coagulation & Fibrinolysis
Verified
Journal Article
Closed access
ADAbdullah Dogan
Abdullah Dogan
FAFatih Aksoy
Fatih Aksoy
AIAtilla Icli
Atilla Icli
AAAkif Arslan
Akif Arslan
EVErcan Varol
Ercan Varol
DEDogan Erdogan
Dogan Erdogan
We investigated the association of mean platelet volume (MPV) with culprit lesion severity and major cardiac outcomes (MCOs) in patients with acute coronary syndrome (ACS) with non-ST elevation (NSTE). This study included 344 patients with NSTE-ACS who had significant coronary stenosis at least 50%. They were divided into high MPV group (n = 109, upper tertile >9.9 fl) and low MPV group (n = 235, lower and mid tertile ≤9.9 fl) according to MPV values on admission. They were followed up for MCOs during 12 months. MCO consisted of the composite end-point of cardiac death, myocardial infarction (MI), recurrent angina or hospitalization. High MPV was independently associated with NSTE-MI [odds ratio (OR) 4.24, 95% confidence interval (CI) 2.52–7.15, P = 0.001] and severe culprit stenosis (≥80%) (OR 4.05, 95% CI 2.39–6.83, P = 0.001). MPV of 9.9 fl was predictive of severe culprit stenosis with a sensitivity of 73% and specificity of 77% (P < 0.001). At 12 months, MCO rate was higher in high MPV group than low MPV group (39 vs. 26%; P = 0.016). This difference resulted from death (6.4 vs. 2.1; P = 0.06) and recurrent angina (16.5 vs. 8.9%; P = 0.045). The MCO-free survival was worse in patients with high MPV than those with low MPV (61 vs. 74%; P = 0.01). In Cox regression analysis, high MPV remained an independent predictor of MCO (hazard ratio 1.52, 95% CI 1.01–2.29, P = 0.04) after adjusting for baseline characteristics. Elevated MPV was independently associated with NSTE-MI presentation and severity of culprit stenosis in NSTE-ACS patients. Moreover, MPV greater than 9.9 fl was predictive of a 12-month MCO.